Limitations of animal models include their inherent technical complexity, the need to perturb some systems to increase sensitivity, difficulties in adapting their use to automated platforms, difficulties in ranking predicted risk against clinical outcomes and translational differences between a selected model species and the human condition. The relevance, sensitivity and analytical depth offered by DrugPrint® analysis of human cardiac models provides a valuable extension to and replacement of current animal assays.
DrugPrint® provides a comprehensive drug profile of QT, arrhythmia and specific ion channel perturbations, providing a multi factorial ‘data rich’ profile to assist in accurate decision-making in the drug development pathway.
The DrugPrint® analysis provides, quick, data-rich output in manual & automated reports which can be adapted for individual clients or regulators needs, significantly reducing data analysis times.
Fast & accurate assessments using MEA based assays early in drug development should significantly reduce the number of compounds that fail in later stages. This increases public safety & confidence in new drug treatments whilst also reducing drug development risks / costs & reliance on whole animal studies.
DrugPrint® is a sophisticated and highly sensitive system for the rapid detection, identification and evaluation of ion channel perturbations and prediction of potential cardiotoxic side effects of new and existing drugs.